Molecular Dynamics Simulation of Solvent-Polymer Interdiffusion. I. Fickian diffusion

The interdiffusion of a solvent into a polymer melt has been studied using large scale molecular dynamics and Monte Carlo simulation techniques. The solvent concentration profile and weight gain by the polymer have been measured as a function of time. The weight gain is found to scale as t^{1/2}, which is expected for Fickian type of diffusion. The concentration profiles are fit very well assuming Fick's second law with a constant diffusivity. The diffusivity found from fitting Fick's second law is found to be independent of time and equal to the self diffusion constant in the dilute solvent limit. We separately calculated the diffusivity as a function of concentration using the Darken equation and found that the diffusivity is essentially constant for the concentration range relevant for interdiffusion.Comment: 17 pages and 7 figure

Contribución a la peligrosidad sísmica de las fallas activas de la zona intraplaca de Iberia: la Falla Alentejo-Plasencia

We present the earthquake potential characterisation of the Alentejo-Plasencia Fault (APF) in the intraplate area of the Iberian Peninsula. The APF displays clear deformation of geomorphic surfaces and sediments of Neogene and younger age and, thus, we consider it to be active within the current tectonic regime. APF fault slip rate values range from 0.01 to 0.1 mm/yr with a preferred value of 0.05 mm/yr. Mw associated to fault rupture ranges from 6.6 to 8.7 using different segmentation models (segments ranging from 20 to 500 km) and various fault scaling relationships. Recurrence intervals derived from slip rate and Mw range from 10 ka to 4 Ma, with preferred values between 20 and 30 ka. Other faults in the interior of Iberia present similar values. Hazard curves produced using all fault sources from the intraplate Iberia show that active faults of the intraplate Iberia do not contribute significantly to seismic hazard at short return periods typical of the building codes (~ 500 year return periods). However, they can be important contributors to hazard at critical facilities (high hazard dams, nuclear power plants, emergency response buildings) where return periods of interest may be 10,000 years or more. Our fault source characterisation is very preliminary (with large uncertainties) and further detailed studies of active faults across the whole plate boundary are required to confirm the values for the intraplate faults presented here.En este trabajo se presenta la caracterización del potencial sísmico de la falla Alentejo-Plasencia (APF) situada en la región intraplaca de la Península Ibérica. La APF muestra una clara deformación de superficies geomorfológicas y sedimentos de edad neógena y más reciente, de modo que la consideramos una falla activa dentro del régimen tectónico vigente. Los valores de velocidad de movimiento de la APF van de 0.01 a 0.1 mm/yr con un valor preferido de 0.05 mm/yr. El valor de magnitud Mw asociada a la falla oscila entre 6.6 y 8.7 utilizando diferentes modelos de segmentación (con longitudes de segmento que van de 20 a 500 km) y varias relaciones de escala. Los intervalos de recurrencia derivados de la velocidad de movimiento y de la Mw oscilan de 10 Ka a 4 Ma, estando los valores preferidos entre los 20 Ka y los 30 Ka. Otras fallas en el interior de Iberia presentan valores similares. Las curvas de peligrosidad generadas utilizando todas las fallas-fuente de la zona intraplaca de Iberia muestran que las fallas activas de esta zona no contribuyen de forma significativa a la peligrosidad sísmica para los cortos periodos de retorno generalmente considerados en los códigos de construcción (para períodos de retorno de ~ 500 años). Sin embargo, dichas fallas pueden contribuir de modo importante a la peligrosidad sísmica para instalaciones críticas (presas de elevado riesgo, centrales nucleares, edificios de servicios de emergencia) donde los periodos de retorno de interés pueden ser de 10.000 años o más. Nuestra caracterización de la falla como fuente sismogénica es muy preliminar (presenta importantes incertidumbres) y se requieren estudios detallados adicionales de las fallas activas a lo largo de todo el límite de placa para confirmar los valores de las fallas intraplaca presentados aquí

Seismic hazard assessment of Navarre (Northern Spain)

The RISNAV project, financed by the Civil Defence Department of Navarre (Northern Spain), aims at assessing seismic risk of the entire region. The final goal of the project is the definition of emergency plans for future earthquakes. With this purpose, four main topics are covered: seismic hazard characterization, geotechnical classification, vulnerability assessment and damage estimation. In this work, the seismic hazard and vulnerability assessment studies are presented

Assessment of Level and Quality of Water Supply Service Delivery for Development of Decision Support Tools: Case Study Asmara Water Supply

The available water sources in many parts of the world are becoming depleted and the problem is compounded by the rate at which populations and rate of demand are increasing. The scarcity of water for urban use is the major problem in many developing countries. With increasing pressures due to urbanisation, population growth, aging infrastructure, climate change, coupled with an unsustainable conventional water management, cities and urban areas in developing countries are facing enormous difficulties and will experience huge challenges in future to manage efficiently the scarcer and less reliable water resources. In some countries, water service quality may be low, service provider

Podoconiosis in East and West Gojam Zones, Northern Ethiopia

Background: Podoconiosis is a neglected tropical disease (NTD) that is prevalent in red clay soil-covered highlands of tropical Africa, Central and South America, and northern India. It is estimated that up to one million cases exist in Ethiopia. This study aimed to estimate the prevalence of podoconiosis in East and West Gojam Zones of Amhara Region in northern Ethiopia. Methodology/Principal Findings: A cross-sectional household survey was conducted in Debre Eliyas and Dembecha woredas (districts) in East and West Gojam Zones, respectively. The survey covered all 17,553 households in 20 kebeles (administrative subunits) randomly selected from the two woredas. A detailed structured interview was conducted on 1,704 cases of podoconiosis identified in the survey. Results: The prevalence of podoconiosis in the population aged 15 years and above was found to be 3.3% (95% CI, 3.2% to 3.6%). 87% of cases were in the economically active age group (15–64 years). On average, patients sought treatment five years after the start of the leg swelling. Most subjects had second (42.7%) or third (36.1%) clinical stage disease, 97.9% had mossy lesions, and 53% had open wounds. On average, patients had five episodes of acute adenolymphangitis (ALA) per year and spent a total of 90 days per year with ALA. The median age of first use of shoes and socks were 22 and 23 years, respectively. More men than women owned more than one pair of shoes (61.1% vs. 50.5%; x2 = 11.6 p = 0.001). At the time of interview, 23.6% of the respondents were barefoot, of whom about two-thirds were women. Conclusions: This study showed high prevalence of podoconiosis and associated morbidities such as ALA, mossy lesions and open wounds in northern Ethiopia. Predominance of cases at early clinical stage of podoconiosis indicates the potential for reversing the swelling and calls for disease prevention interventions

Corrigendum to “Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy” [Neuromuscular Disorders, Vol. 30 (6) 2020, 492-502] (Neuromuscular Disorders (2020) 30(6) (492–502), (S0960896620301188), (10.1016/j.nmd.2020.05.002))

This article reported on the results from a phase 2 trial of domagrozumab and its open-label extension in patients with Duchenne muscular dystrophy (Clinicaltrials.gov identifiers: NCT02310763 and NCT02907619). The manuscript also provided results on two secondary endpoints for magnetic resonance imaging (MRI), muscle volume and muscle volume index. The authors regret that, following publication of the results and in preparation for a separate publication on MRI results from this trial, the MRI images were reviewed and segmentation errors were identified. As a result, the team worked to (1) Perform a rigorous quality inspection of all analysed data; (2) Identify cases where there were incorrect segmentations; (3) correct segmentation errors; (4) Re-analyse all data with correct segmentation. Using the updated MRI data, the MMRM analysis showed there was a change in the significance of secondary endpoints evaluating Thigh Muscle Volume and Muscle Volume Index. No significant differences between treatment groups in muscle volume measures were found in the original analysis. These results have not altered the overall interpretation of the study results but do necessitate revisions to the article. These data confirm that the trial design and execution adequately tested the hypothesis that myostatin inhibition would slow or delay the loss of function in patients with Duchenne muscular dystrophy (DMD). The increase in muscle volume observed by MRI in patients with DMD treated with domagrozumab is in accordance with mechanism of action for domagrozumab, which targets myostatin, a negative regulator of muscle growth. The increase in muscle volume did not lead to a clinical benefit in patients with DMD. The primary endpoint (4 stair climb) did not meet statistical significance, nor did the other functional tests. The study was terminated due to lack of efficacy. Full details of the needed revisions are as follows: 1. In the results section 3.6 (page 8, second paragraph), we reported no significant differences in mean percent change from baseline between domagrozumab and placebo for both muscle volume and muscle volume index. This paragraph was replaced with the following text: “There was a significant difference between domagrozumab and placebo in the mean percent change from baseline in thigh muscle volume at Week 17 (difference 2.945%, P=0.0087) and Week 49 (differences 4.087%, P=0.0298), and in muscle volume index at Week 33 (difference 2.612%, P=0.0376) and Week 49 (differences3.208%, P=0.0411).” 2. In the discussion (page 9), the following sentence, “Although neither muscle volume nor muscle volume index measures were statistically significant in this study, they are both consistent with a potential anabolic effect.” was replaced with, “The increase in muscle volume observed on MRI in patients with DMD treated with domagrozumab, is in accordance with mechanism of action for this compound which targets myostatin, a negative regulator of muscle growth. However, the increase in muscle volume did not lead to a clinical benefit (improved function) in patients with DMD.” 3. In view of the correction to the Results section, this is now reflected in the abstract which has changed to read: “There were no significant between-group differences in secondary clinical endpoints, except for the thigh muscle volume and muscle volume index measures (P\u3c0.05).” The authors would like to apologise for any inconvenience caused